Continuing Education

HSCO 2022 Annual Conference

Saturday, November 5
The Kahala Hotel & Resort
Honolulu, HI

Agenda

7:00 AM
Registration / Networking Breakfast

8:00 AM
Welcome and Introductions
Michael Carney, MD
President, Hawaii Society of Clinical Oncology

8:30 AM
State and Federal Policy Updates
Blake Oshiro, Capitol Consultants of Hawaii
Christian G. Downs, JD, MHA, ACCC

9:15 AM
Update on Engineered Cell Therapies: CAR-T and Beyond
Stephen Grupp, MD, PHD
Children’s Hospital of Philadelphia

10:00 AM
Networking Break / Resource Center

10:30 AM
Integrative Cancer Care
Donald Abrams, MD
University of California, San Francisco

11:15 AM
How to Keep Up with the Cancer Literature: Challenges with Recent Studies
Vinay Prasad, MD, MPH
University of California, San Francisco

12:00 PM
Lunch

1:00 PM
The Latest and Greatest in Targeted Therapy for Breast Cancer
Sara Hurvitz, MD, FACP
University of California, Los Angeles

1:45 PM
Precision Medicine: Opportunities and Controversies
Emil Lou, MD, PhD, FACP
Masonic Cancer Center, University of Minnesota

2:30 PM
Networking Break / Resource Center

3:00 PM
Local Clinical Trials Update

Breast Cancer
Jami Fukui, MD
Hawaii Pacific Health, Kapiolani Medical Center for Women & Children

Pediatrics
Wade Kyono, MD
Hawaii Pacific Health, Kapiolani Medical Center for Women & Children

Liver Cancer
Jared Acoba, MD
University of Hawaii Cancer Center

4:00 PM
Closing Remarks

Agenda as of 10.19.22 and subject to change.

Learning Objectives

At the end of this educational activity, participants should be able to:

Summarize recent clinical trial findings related to various cancers, including breast cancer, liver cancer, blood cancers, and pediatric cancers.
Use new knowledge about CAR T-cell therapy and other immunotherapies to inform decisions related to the treatment of some cancers.
Describe how next-generation sequencing enables more precise care for patients.
Provide patients who are seeking more holistic care with information on integrative oncology.
Apply strategies that can help them better manage and assess the literature.
Detail state and federal policies affecting the practice of oncology.

Disclosure Information

Boston University School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.

Planners/Speakers

Name of Planner/Speaker	Reported Financial Relationship

Donald Abrams, MD	Donald Abrams is a consultant and speaker with Clever Leaves and Maui Wellness Group, a speaker for GW Pharmaceuticals and a consultant for Wellkasa. He does plan to discuss unlabeled/investigational uses of a product.
Jared Acoba, MD	Jared Acoba, MD, receives grant research support from GSK. He does plan to discuss unlabeled/investigational uses of a product.
Christa Braun-Inglis, DNP, APRN, FNP-BC, AOCNP	No relevant financial relationships.
Michael Carney, MD	No relevant financial relationships.
Christian Downs, JD, MHA	No relevant financial relationships.
Jami Fukui, MD	No relevant financial relationships.
Regina Gibson- Burtnick, BBA, CAE	No relevant financial relationships with ineligible companies.
Stephen Grupp, MD, PhD	Stephan Grupp, MD, PhD receives grant research support from Novartis, Kite, Vertex, and Servier; is a consultant for Novartis, Roche, GSK, Humanige; and receives SCCs from Novartis, Jazz, Adaptimmune, TCR2, Cellectis, Juno, Vertex, Allogene, and Cabaletta. He does not plan to discuss unlabeled/investigational uses of a product.
Lynette Henshaw, PharmD, CME Reviewer	No relevant financial relationships.
Sara Hurvitz, MD, FACP	Sara Hurvitz, MD, FACP, is a consultant, speaker, and receives grant research support from Daiichi Sankyo; and receives grant research support from Ambrx, Amgen, Arvinas, AstraZeneca, Bayer, Cytomx, Daiichi-Sankyo, Dantari, Dignitana, Genentech/Roche, G1-Therapeutics, Gilead, GSK, Immunomedics, Eli Lilly, MacroGenics, Novartis, OBI Pharma, Orinove, Pfizer, Phoenix Molecular Designs, Ltd., Pieris, PUMA, Radius, Samumed, Sanofi, Seattle Genetics/Seagen, Zymeworks Coming soon: Celcuity, Greenwich Life Sciences Inc., Stemline, Orum, Very. She does plan to discuss unlabeled/investigational uses of a product.
Emil Lou, MD, PhD, FACP	Emil Lou, MD, PhD, FACP, is a consultant, speaker and receives grant research support from Novocure, LLC; is a speaker and receives grant research support from Antidote Education; receives grant research support from Intima Biosciences and Celgene. He does plan to discuss unlabeled/investigational uses of a product.
Sandra Megally	No relevant financial relationships.
Naomi Moeller, Boston University School of Medicine CME/CNE Office	No relevant financial relationships.
Shane Morita, MD	No relevant financial relationships.
Ryon Nakasone, MD	No relevant financial relationships.
Ian Okazaki, MD	No relevant financial relationships.
Jasmine Patel, PharmD, CME Reviewer	Jasmine Patel, PharmD, is a speaker for AbbVie and was on the Myovant Ad Board.
Vinay Prasad, MD, MPH	Vinay Prasad, MD, MPH, receives grant research support from Arnold Ventures; is a consultant with UnitedHealthcare and OptumRx; receives royalties from Johns Hopkins Press, Medscape and MedPage; collects subscriber fees from YouTube, Substack and Patreon. He does plan to discuss unlabeled/investigational uses of a product.
Amy Smith, CNE Course Advisor	No relevant financial relationships.
David Tamura	David Tamura has no relevant financial relationships. He does plan to discuss unlabeled/investigational uses of a product.
Carmela A. Townsend, DNP, MS, MBA, RN, Lead Nurse Planner, Boston University School of Medicine CME/CNE Office	No relevant financial relationships.

Accreditation Statement

Credit Designation for Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and the Hawaii Society of Clinical Oncology.

Boston University School of Medicine designates this live activity for a maximum of 5.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Credit Designation for Nurses

Boston University School of Medicine Continuing Nursing Education is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity has been provided by Boston University School of Medicine Continuing Nursing Education and jointly provided by the Hawaii Society of Clinical Oncology.

Contact Hours: 5.50, of which 3.15 is pharmacology credit worthy

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. Trustees of Boston University makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will trustees of Boston University be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care. In no event should information in the materials regarding laws, regulations, or legal liability be considered legal advice or used as a substitute for consulting with an attorney.